Bristol Myers Squibb Company $BMY Stock Sold by Harbour Investments Inc.

Harbour Investments Inc. trimmed its stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 38.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 30,629 shares of the biopharmaceutical company’s stock after selling 19,483 shares during the quarter. Harbour Investments Inc.’s holdings in Bristol Myers Squibb were worth $1,912,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Lazard Asset Management LLC boosted its position in shares of Bristol Myers Squibb by 23.7% during the first quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after buying an additional 368,193 shares during the period. Callan Family Office LLC acquired a new position in Bristol Myers Squibb during the 2nd quarter valued at about $3,575,000. Saudi Central Bank increased its stake in Bristol Myers Squibb by 90.2% during the 2nd quarter. Saudi Central Bank now owns 142,922 shares of the biopharmaceutical company’s stock valued at $8,235,000 after buying an additional 67,780 shares during the period. BlackRock Inc. raised its position in shares of Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after buying an additional 8,702,106 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in shares of Bristol Myers Squibb by 17.4% during the second quarter. Envestnet Asset Management Inc. now owns 2,142,754 shares of the biopharmaceutical company’s stock valued at $123,465,000 after acquiring an additional 317,360 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Julia Haller sold 3,800 shares of the firm’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the transaction, the director owned 30,279 shares in the company, valued at $1,916,963.49. This represents a 11.15% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $59.49 on Thursday. The company has a market capitalization of $121.61 billion, a PE ratio of 13.19, a PEG ratio of 0.32 and a beta of 0.20. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. The company’s 50 day moving average price is $61.65 and its 200 day moving average price is $60.41. Bristol Myers Squibb Company has a 52 week low of $45.26 and a 52 week high of $68.64.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The company had revenue of $13.07 billion during the quarter, compared to analyst estimates of $12.72 billion. During the same quarter last year, the business posted $1.63 EPS. The company’s revenue for the quarter was up 6.9% on a year-over-year basis. Research analysts expect that Bristol Myers Squibb Company will post 6.46 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were paid a $0.63 dividend. The ex-dividend date was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is 55.88%.

Key Stories Impacting Bristol Myers Squibb

These are some of the BMY stories that stood out recently:

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. UBS Group cut Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. Roth Capital initiated coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating and a $75.00 target price for the company. Cantor Fitzgerald decreased their price target on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a research report on Thursday, October 8th. JPMorgan Chase & Co. boosted their target price on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Finally, Daiwa Securities Group lifted their price target on Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and an average price target of $65.46.

Get Our Latest Report on Bristol Myers Squibb

About Bristol Myers Squibb

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Further Reading

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).

Institutional Ownership by Quarter for Bristol Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.